EE05423B1 - IL-18 inhibiitori kasutamine maksakahjustuse ja muude haiguste raviks v?i ennetamiseks sobiva ravimi valmistamiseks, vektori ja raku kasutamine inhibiitori produtseerimisel ning IL-18 inhibiitorit sisaldav farmatseutiline kompositsioon - Google Patents

IL-18 inhibiitori kasutamine maksakahjustuse ja muude haiguste raviks v?i ennetamiseks sobiva ravimi valmistamiseks, vektori ja raku kasutamine inhibiitori produtseerimisel ning IL-18 inhibiitorit sisaldav farmatseutiline kompositsioon

Info

Publication number: EE05423B1
Authority: EE; Estonia
Prior art keywords: inhibitor; manufacture; medicament; prevention; treatment
Prior art date: 2000-02-21

Application number

EEP200200463A

Other languages

English (en)

Estonian (et)

Inventor

Chvatchko Yolande

Dinarello Charles

Plater-Zyberk Christine

Van Deventer Santer

Rubinstein Menachem

Novick Daniela

Kim Soo-Hyun

Original Assignee

Applied Research Systems Ars Holding N.V.

Yeda Research And Development Co. Ltd.

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2000-02-21

Filing date

2001-02-20

Publication date

2011-06-15

2001-02-20 Application filed by Applied Research Systems Ars Holding N.V., Yeda Research And Development Co. Ltd. filed Critical Applied Research Systems Ars Holding N.V.

2003-12-15 Publication of EE200200463A publication Critical patent/EE200200463A/xx

2011-06-15 Publication of EE05423B1 publication Critical patent/EE05423B1/xx

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
- C07K16/244—Interleukins [IL]
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A61P25/32—Alcohol-abuse
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Medicinal Chemistry (AREA)
General Health & Medical Sciences (AREA)
Organic Chemistry (AREA)
Veterinary Medicine (AREA)
Pharmacology & Pharmacy (AREA)
Public Health (AREA)
Animal Behavior & Ethology (AREA)
Bioinformatics & Cheminformatics (AREA)
Engineering & Computer Science (AREA)
Chemical Kinetics & Catalysis (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
General Chemical & Material Sciences (AREA)
Immunology (AREA)
Physical Education & Sports Medicine (AREA)
Mycology (AREA)
Rheumatology (AREA)
Microbiology (AREA)
Epidemiology (AREA)
Biophysics (AREA)
Molecular Biology (AREA)
Proteomics, Peptides & Aminoacids (AREA)
Genetics & Genomics (AREA)
Addiction (AREA)
Biochemistry (AREA)
Orthopedic Medicine & Surgery (AREA)
Oncology (AREA)
Gastroenterology & Hepatology (AREA)
Biomedical Technology (AREA)
Pain & Pain Management (AREA)
Neurology (AREA)
Neurosurgery (AREA)
Psychiatry (AREA)
Communicable Diseases (AREA)
Virology (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Peptides Or Proteins (AREA)
Preparation Of Compounds By Using Micro-Organisms (AREA)

EEP200200463A 2000-02-21 2001-02-20 IL-18 inhibiitori kasutamine maksakahjustuse ja muude haiguste raviks v?i ennetamiseks sobiva ravimi valmistamiseks, vektori ja raku kasutamine inhibiitori produtseerimisel ning IL-18 inhibiitorit sisaldav farmatseutiline kompositsioon EE05423B1 (et)

Applications Claiming Priority (5)

Application Number	Priority Date	Filing Date	Title
EP00103590		2000-02-21
EP00103597		2000-02-21
EP00121651		2000-10-04
EP00125633		2000-11-23
PCT/EP2001/001867 WO2001062285A1 (en)	2000-02-21	2001-02-20	Use of il-18 inhibitors

Publications (2)

Publication Number	Publication Date
EE200200463A EE200200463A (et)	2003-12-15
EE05423B1 true EE05423B1 (et)	2011-06-15

Family

ID=27439934

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
EEP200200463A EE05423B1 (et)	2000-02-21	2001-02-20	IL-18 inhibiitori kasutamine maksakahjustuse ja muude haiguste raviks v?i ennetamiseks sobiva ravimi valmistamiseks, vektori ja raku kasutamine inhibiitori produtseerimisel ning IL-18 inhibiitorit sisaldav farmatseutiline kompositsioon

Country Status (31)

Country	Link
US (1)	US20030157094A1 (sr)
EP (1)	EP1257292B1 (sr)
JP (1)	JP4744763B2 (sr)
KR (3)	KR20070057282A (sr)
CN (1)	CN1322897C (sr)
AT (1)	ATE506959T1 (sr)
AU (2)	AU2001240636B8 (sr)
BG (1)	BG66134B1 (sr)
BR (1)	BR0108514A (sr)
CA (2)	CA2399298C (sr)
CY (1)	CY1111687T1 (sr)
CZ (1)	CZ304485B6 (sr)
DE (1)	DE60144514D1 (sr)
DK (1)	DK1257292T3 (sr)
EA (1)	EA005583B1 (sr)
EE (1)	EE05423B1 (sr)
HK (1)	HK1051965A1 (sr)
HR (1)	HRP20020652A2 (sr)
HU (1)	HU227752B1 (sr)
IL (2)	IL151388A0 (sr)
ME (1)	ME00546B (sr)
MX (1)	MXPA02008079A (sr)
NO (1)	NO331971B1 (sr)
NZ (3)	NZ546294A (sr)
PL (1)	PL206549B1 (sr)
PT (1)	PT1257292E (sr)
RS (1)	RS51737B (sr)
SI (1)	SI1257292T1 (sr)
SK (1)	SK288032B6 (sr)
TR (2)	TR200502508T2 (sr)
WO (1)	WO2001062285A1 (sr)

Families Citing this family (25)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
AU2001236807A1 (en) *	2000-02-10	2001-08-20	Abbott Laboratories	Antibodies that bind human interleukin-18 and methods of making and using
KR20070057282A (ko) *	2000-02-21	2007-06-04	어플라이드 리서치 시스템스 에이알에스 홀딩 엔.브이.	Ｉｌ-18 저해물질의 용도
US6894155B2 (en)	2000-10-11	2005-05-17	Viron Therapeutics	Nucleic acid molecules and polypeptides for immune modulation
US7718368B2 (en)	2000-12-04	2010-05-18	Viron Therapeutics Inc.	Immunomodulatory protein and useful embodiments thereof
BR0210904A (pt) *	2001-05-16	2005-08-16	Yeda Res & Dev	Uso de inibidores de il-18 para o tratamento ou prevenção de sepse
MXPA04002565A (es) *	2001-11-30	2004-05-31	Pfizer Prod Inc	Combinacion de un inhibidor de il-1/18 con un inhibidor de tnf para el tratamiento de inflamacion.
WO2004064713A2 (en) *	2003-01-20	2004-08-05	Vib Vzw	The use of yop preoteins or rho gtpase inhibitors as caspase-1 inhibitors
JP4134166B2 (ja) *	2003-04-30	2008-08-13	独立行政法人科学技術振興機構	ヒト抗ヒトインターロイキン−１８抗体およびその断片、並びにそれらの利用方法
CA2545733A1 (en) *	2003-11-10	2005-05-26	Vertex Pharmaceuticals Incorporated	Methods for monitoring il-18
US7968684B2 (en) *	2003-11-12	2011-06-28	Abbott Laboratories	IL-18 binding proteins
NZ552908A (en)	2004-06-30	2009-11-27	Atsuo Sekiyama	Indicator agent for noninflammatory stress response and use thereof
DK1808446T3 (da) *	2004-07-16	2012-05-14	Atsuo Sekiyama	IL-18-receptor-antagonist og farmaceutisk sammensætning indeholdende antagonisten
SI2267024T1 (sl)	2005-06-03	2012-09-28	Ares Trading Sa	Proizvodnja rekombinantnega IL-18 vezavnega proteina
ES2375831T3 (es)	2005-06-10	2012-03-06	Ares Trading S.A.	Procedimiento para la purificación de prote�?nas de unión a il-18.
EP1746167A1 (en) *	2005-07-20	2007-01-24	Apoxis SA	Method for the identification of compounds susceptible to inhibit inflammation
ES2514495T3 (es)	2006-05-25	2014-10-28	Glaxo Group Limited	Anticuerpos humanizados modificados anti-interleucina-18
US8440195B2 (en) *	2010-11-12	2013-05-14	National University Corporation Chiba University	Inhibition of CD69 for treatment of inflammatory conditions
GB201213968D0 (en) *	2012-08-06	2012-09-19	Isis Innovation	Prevention and treatment of osteoarthritis
KR102512797B1 (ko) *	2013-09-05	2023-03-22	에이비2 바이오 에스에이	염증성 질환에서 il-18 결합 단백질(ｉｌ-18ｂｐ)
CN107660150B (zh)	2015-03-05	2023-10-24	Ab2生物股份有限公司	Il-18结合蛋白(il-18bp)和抗体在炎性疾病中
CN106109497A (zh) *	2016-07-25	2016-11-16	深圳爱生再生医学科技有限公司	治疗肝硬化的干细胞制剂
CN106834449B (zh) *	2017-01-10	2019-04-30	东南大学	与原发性胆汁性胆管炎关联的白细胞介素21受体及其应用
CN112236453A (zh) *	2018-06-14	2021-01-15	波尔多大学	使用白细胞介素-1抑制剂治疗胎盘慢性组织细胞绒毛间质炎
JPWO2023286694A1 (sr)	2021-07-13	2023-01-19
CN117647645B (zh) *	2024-01-29	2024-04-12	中国人民解放军总医院第一医学中心	Lbp、atf6、m-csfr联用在制备诊断自身免疫性肝病产品中的应用及试剂盒

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US5985863A (en) *	1996-09-12	1999-11-16	Vertex Pharmaceuticals, Inc.	Compositions and methods for decreasing IGIF and IFN-γ production by administering an ICE inhibitor
US5116964A (en) *	1989-02-23	1992-05-26	Genentech, Inc.	Hybrid immunoglobulins
US5744451A (en) *	1995-09-12	1998-04-28	Warner-Lambert Company	N-substituted glutamic acid derivatives with interleukin-1 β converting enzyme inhibitory activity
EP0936923B1 (en) *	1996-11-15	2003-12-17	Kennedy Institute Of Rheumatology	SUPPRESSION OF TNFalpha AND IL-12 IN THERAPY
US7141393B2 (en) *	1996-12-26	2006-11-28	Kabushiki Kaisha Hayashibara Seibutsu Kagaku Kenkyujo	Interleukin-18-receptor proteins
JP4026923B2 (ja) *	1997-03-12	2007-12-26	株式会社林原生物化学研究所	ポリペプチド
US6087116A (en) *	1997-03-12	2000-07-11	Kabushiki Kaisha Hayashibara Seibutsu Kagaku Kenkyujo	Interleukin-18 (IL-18) receptor polypeptides and their uses
IL121860A0 (en) *	1997-08-14	1998-02-22	Yeda Res & Dev	Interleukin-18 binding proteins their preparation and use
CA2276216A1 (en) *	1998-06-24	1999-12-24	Kabushiki Kaisha Hayashibara Seibutsu Kagaku Kenkyujo	An artificial peptide capable of neutralizing the biological activity of interleukin-18
EP1110969A4 (en) *	1998-09-01	2002-01-09	Hayashibara Biochem Lab	INTERLEUKIN 18 BINDING PROTEIN
AR022952A1 (es) *	1999-03-19	2002-09-04	Smithkline Beecham Corp	ANTICUERPO MONOCLONAL DE ROEDOR ESPECIFICAMENTE NEUTRALIZANTE PARA LA INTERLEUQUINA-18 HUMANA , UN FRAGMENTO FAB NEUTRALIZANTE o FRAGMENTO F(AB')2, UNA REGION DE COMPLEMENTARIEDAD DE CADENA LIGERA DE INMONOGLOBULINA(CDR), UNA MOLECULA DE ACIDO NUCLEICO, COMPOSICION FARMACEUTICA QUE LO COMPRENDE, EL
AU2001236807A1 (en) *	2000-02-10	2001-08-20	Abbott Laboratories	Antibodies that bind human interleukin-18 and methods of making and using
KR20070057282A (ko) *	2000-02-21	2007-06-04	어플라이드 리서치 시스템스 에이알에스 홀딩 엔.브이.	Ｉｌ-18 저해물질의 용도
WO2002032374A2 (en) *	2000-10-18	2002-04-25	Immunex Corporation	Methods for treating il-18 mediated disorders

2001
- 2001-02-20 KR KR1020077010853A patent/KR20070057282A/ko not_active Application Discontinuation
- 2001-02-20 AT AT01911662T patent/ATE506959T1/de active
- 2001-02-20 MX MXPA02008079A patent/MXPA02008079A/es active IP Right Grant
- 2001-02-20 EE EEP200200463A patent/EE05423B1/xx unknown
- 2001-02-20 SI SI200130994T patent/SI1257292T1/sl unknown
- 2001-02-20 IL IL15138801A patent/IL151388A0/xx unknown
- 2001-02-20 EP EP01911662A patent/EP1257292B1/en not_active Expired - Lifetime
- 2001-02-20 ME MEP-2008-639A patent/ME00546B/me unknown
- 2001-02-20 DK DK01911662.3T patent/DK1257292T3/da active
- 2001-02-20 NZ NZ546294A patent/NZ546294A/en not_active IP Right Cessation
- 2001-02-20 US US10/204,387 patent/US20030157094A1/en not_active Abandoned
- 2001-02-20 BR BR0108514-0A patent/BR0108514A/pt not_active Application Discontinuation
- 2001-02-20 CA CA2399298A patent/CA2399298C/en not_active Expired - Lifetime
- 2001-02-20 JP JP2001561349A patent/JP4744763B2/ja not_active Expired - Lifetime
- 2001-02-20 HU HU0300061A patent/HU227752B1/hu unknown
- 2001-02-20 DE DE60144514T patent/DE60144514D1/de not_active Expired - Lifetime
- 2001-02-20 PL PL357554A patent/PL206549B1/pl unknown
- 2001-02-20 KR KR1020027010645A patent/KR20020086540A/ko not_active Application Discontinuation
- 2001-02-20 TR TR2005/02508T patent/TR200502508T2/xx unknown
- 2001-02-20 AU AU2001240636A patent/AU2001240636B8/en not_active Expired
- 2001-02-20 PT PT01911662T patent/PT1257292E/pt unknown
- 2001-02-20 EA EA200200890A patent/EA005583B1/ru not_active IP Right Cessation
- 2001-02-20 CN CNB018052932A patent/CN1322897C/zh not_active Expired - Lifetime
- 2001-02-20 NZ NZ520122A patent/NZ520122A/en not_active IP Right Cessation
- 2001-02-20 RS YU60402A patent/RS51737B/sr unknown
- 2001-02-20 AU AU4063601A patent/AU4063601A/xx active Pending
- 2001-02-20 SK SK1208-2002A patent/SK288032B6/sk not_active IP Right Cessation
- 2001-02-20 CZ CZ2002-2843A patent/CZ304485B6/cs not_active IP Right Cessation
- 2001-02-20 TR TR2002/02030T patent/TR200202030T2/xx unknown
- 2001-02-20 WO PCT/EP2001/001867 patent/WO2001062285A1/en active IP Right Grant
- 2001-02-20 NZ NZ535299A patent/NZ535299A/en not_active IP Right Cessation
- 2001-02-20 CA CA2683009A patent/CA2683009C/en not_active Expired - Lifetime
- 2001-02-20 KR KR1020077018043A patent/KR20070087256A/ko not_active Application Discontinuation
2002
- 2002-08-01 HR HRP20020652 patent/HRP20020652A2/hr not_active Application Discontinuation
- 2002-08-20 BG BG107018A patent/BG66134B1/bg unknown
- 2002-08-20 NO NO20023962A patent/NO331971B1/no not_active IP Right Cessation
- 2002-08-21 IL IL151388A patent/IL151388A/en active IP Right Grant
2003
- 2003-06-12 HK HK03104196A patent/HK1051965A1/xx unknown
2011
- 2011-07-13 CY CY20111100682T patent/CY1111687T1/el unknown

Also Published As

Publication number	Publication date
AU4063601A (en)	2001-09-03
CA2399298C (en)	2014-04-15
NO331971B1 (no)	2012-05-14
HRP20020652A2 (en)	2004-12-31
DK1257292T3 (da)	2011-07-18
KR20070087256A (ko)	2007-08-27
KR20020086540A (ko)	2002-11-18
YU60402A (sh)	2005-09-19
NZ546294A (en)	2008-02-29
EE200200463A (et)	2003-12-15
CZ304485B6 (cs)	2014-05-28
PL357554A1 (en)	2004-07-26
AU2001240636B2 (en)	2005-10-13
BR0108514A (pt)	2002-12-17
SK12082002A3 (sk)	2003-05-02
BG107018A (bg)	2003-09-30
JP2003523403A (ja)	2003-08-05
CN1322897C (zh)	2007-06-27
KR20070057282A (ko)	2007-06-04
DE60144514D1 (de)	2011-06-09
HUP0300061A3 (en)	2005-09-28
TR200502508T2 (tr)	2007-04-24
RS51737B (sr)	2011-10-31
HU227752B1 (en)	2012-02-28
US20030157094A1 (en)	2003-08-21
CN1404400A (zh)	2003-03-19
CA2683009A1 (en)	2001-08-30
BG66134B1 (bg)	2011-06-30
TR200202030T2 (tr)	2003-01-21
CY1111687T1 (el)	2015-10-07
IL151388A0 (en)	2003-04-10
EA005583B1 (ru)	2005-04-28
EA200200890A1 (ru)	2003-02-27
SK288032B6 (sk)	2012-12-03
NO20023962L (no)	2002-08-20
EP1257292A1 (en)	2002-11-20
IL151388A (en)	2009-09-01
EP1257292B1 (en)	2011-04-27
AU2001240636B8 (en)	2005-11-03
ME00546B (me)	2011-10-10
JP4744763B2 (ja)	2011-08-10
NZ535299A (en)	2006-06-30
HUP0300061A2 (hu)	2003-04-28
CZ20022843A3 (cs)	2003-02-12
HK1051965A1 (en)	2003-08-29
PT1257292E (pt)	2011-07-05
CA2399298A1 (en)	2001-08-30
WO2001062285A1 (en)	2001-08-30
SI1257292T1 (sl)	2011-08-31
CA2683009C (en)	2014-09-23
ATE506959T1 (de)	2011-05-15
NO20023962D0 (no)	2002-08-20
MXPA02008079A (es)	2003-02-27
NZ520122A (en)	2005-04-29
PL206549B1 (pl)	2010-08-31

Publication	Publication Date	Title
EE05423B1 (et)	2011-06-15	IL-18 inhibiitori kasutamine maksakahjustuse ja muude haiguste raviks v?i ennetamiseks sobiva ravimi valmistamiseks, vektori ja raku kasutamine inhibiitori produtseerimisel ning IL-18 inhibiitorit sisaldav farmatseutiline kompositsioon
EP1562897A4 (en)	2007-06-27	PHENYL ACARBOXAMIDE AS A BETA SEKRETASE INHIBITOR FOR THE TREATMENT OF ALZHEIMER
EE04111B1 (et)	2003-08-15	Raku adhesiooni inhibiitorid, nende kasutamine janeid sisaldavad farmatseutilised kompositsioonid
GB0223040D0 (en)	2002-11-13	Therapeutic compounds
BR0214343A (pt)	2004-09-14	Inibidores de 11 - beta - hidroxi esteróide desidrogenase tipo 1
BR0008060A (pt)	2002-02-05	Composições inibidoras de ciclooxigenase-2 tendo rápido inìcio de eficácia terapêutica
GB0005251D0 (en)	2000-04-26	Therapeutic compounds
RS20110578A2 (sr)	2012-08-31	Makrociklične karboksilne kiseline i acilsulfonamidi kao inhibitori replikacije hcv
MXPA05008172A (es)	2005-10-05	Derivados de malonamida como inhibidores gamma-secretasa.
BR0312427A (pt)	2005-04-19	Combinação, uso de uma combinação, método para a produção de um efeito inibitório de ibat em um animal de sangue quente, método de prevenção de diarréia, composição farmacêutica, método de tratamento de condições hiperlipidêmicas em um animal de sangue quente, e, uso de um sal metálico
WO2001035950A3 (en)	2001-11-29	Benzamide therapeutics and methods for treating inflammatory bowel disease
WO2005018545A3 (en)	2005-05-19	Macrocyclic beta-secretase inhibitors for the treatment of alzheimer's disease
CY1114133T1 (el)	2016-07-27	ΥΠΟΚΑΤΕΣΤΗΜΕΝΕΣ γ-ΦΑΙΝΥΛ-Δ-ΛΑΚΤΑΜΕΣ ΚΑΙ ΧΡΗΣΕΙΣ ΠΟΥ ΣΧΕΤΙΖΟΝΤΑΙ ΠΡΟΣ ΑΥΤΕΣ
WO2004105737A3 (en)	2005-06-09	Pharmaceutical compositions and methods relating to inhibiting fibrous adhesions using various agents
AR034343A1 (es)	2004-02-18	Combinaciones farmaceuticas
IL172773A0 (en)	2006-04-10	Formulations for the treatment of arhritis conditions
NO20071399L (no)	2007-05-08	VLA-4-antagonister
WO2003016563A3 (fr)	2004-04-01	Cible moleculaire de la neurotoxicite
BR0206819A (pt)	2004-02-03	Uso de inibidores de il-18 para o tratamento e/ou para a prevenção de doença cardìaca
RS60604A (en)	2006-12-15	Carboxamidine derivatives and their use in the treatment of vascular diseases
TR200502061T2 (tr)	2005-08-22	IL-18 inhibitörlerinin kullanımı.
BR0113886A (pt)	2003-07-15	Composição, composição farmacêutica, tratamento de combinação para prevenir ou inibir a geração ou atividade de trombina num paciente, método para inibir ou prevenir a geração ou atividade de trombina num paciente, uso de uma composição ou tratamento de combinação, uso de uma composição, uso e kit
ATE353221T1 (de)	2007-02-15	Verwendung von gegen candida wirksamen mitteln zur behandlung von störungen der oralen und intestinalen mucosa
WO2003066806A3 (en)	2003-12-24	Therapeutic use of aziridino compounds
TNSN00242A1 (en)	2002-05-30	VALDECOXIB COMPOSITIONS

Legal Events

Date	Code	Title	Description
2007-10-15	GB1A	Change in the ownership or in the address of the owner
2012-04-16	HC1A	Change of owner name